Outsourcing Industry Marked by Considerable Investments in 2016

Publication
Article
BioPharm InternationalBioPharm International-06-15-2016
Volume 2016 ebook
Issue 1
Pages: 39–41

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

The biopharmaceutical outsourcing industry has been marked by investment in technology and facility upgrades, mergers, acquisitions, and development partnerships in 2016. This article details are some of the latest developments in the biopharmaceutical outsourcing market.

Download the

BioPharm International 2016 Outsourcing Resources eBook

.

 

 

 

 

Articles in this issue
BPsupp0616_RT_manufacturing_185.jpg
Contract Service Providers Gear Up to Develop Emerging Therapies
BPsupp0616_RT_business_185.jpg
Biopharma Service Providers Address a Full Plate of Challenges
BPsupp0616_SupplyChain_Vetter_185.jpg
Dealing with Pharmaceutical Supply-Chain Complexities
BPsupp0616_3MDrugDelivery_185.jpg
Keeping it Simple: Collaborating for Success in Drug Delivery
BPsupp0616_china_185.jpg
Regulatory Reform in China: Implications for Global Biopharmaceutical Companies
BPsupp0616_Langer_185.jpg
Biomanufacturers Demand Higher Quality Standards in 2016
BPsupp0616_Parexel_185.jpg
Preventing Phase III Failures
BPsupp0616_CMO-News_185.jpg
Outsourcing Industry Marked by Considerable Investments in 2016
Recent Videos
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Sanofi Invests €40 Million to Boost Antibody Production in France

Feliza Mirasol
November 21st 2024
Article

The investment will allow Sanofi to strengthen antibody bioproduction at its Lyon Gerland site in France.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

BioPharmaSpec Launches Three New R&D Facilities in Europe

Feliza Mirasol
November 20th 2024
Article

The new European facilities located in German, Italy, and Lithuania will specialize in drug discovery and R&D services.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

SEKISUI Completes CDMO Capacity Expansion for CGMP Biopharma Manufacturing

Feliza Mirasol
November 19th 2024
Article

Under a £15.7 million (US$20.7 million) investment, SEKISUI has expanded its UK site for clinical-grade drug substance manufacturing.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Alentis Therapeutics Gains $181.4 Million Funding to Advance Anti-Claudin-1 ADCs in Solid Tumors

Feliza Mirasol
November 18th 2024
Article

With financing led by OrbiMed, Novo Holdings, and Jeito Capital, Alentis Therapeutics will develop a pipeline of Claudin-1-targeted ADCs to treat solid tumors.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Lecanemab Gets Nod from CHMP for Use in Early Alzheimer’s Disease

Felicity Thomas
November 15th 2024
Article

Eisai Europe and Biogen have received a positive opinion for the monoclonal antibody therapy to be used as a treatment of adult patients with early Alzheimer’s disease.

© 2024 MJH Life Sciences

All rights reserved.